Vanguard Personalized Indexing Management
IOVA icon

Vanguard Personalized Indexing Management’s Iovance Biotherapeutics IOVA Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Buy
39,528
+9,724
+33% +$36.9K ﹤0.01% 1965
2026
Q1 		$105K Buy
29,804
+17,167
+136% +$54.9K ﹤0.01% 1944
2025
Q4 		$34.5K Buy
+12,637
New +$29.2K ﹤0.01% 1911
2025
Q2 		– Sell
-23,730
Closed -$79K – 1992
2025
Q1 		$79K Sell
23,730
-253
-1% -$1.3K ﹤0.01% 1642
2024
Q4 		$177K Sell
23,983
-3,864
-14% -$35.8K ﹤0.01% 1546
2024
Q3 		$261K Buy
27,847
+5,762
+26% +$54.6K ﹤0.01% 1411
2024
Q2 		$177K Buy
22,085
+4,726
+27% +$50.6K ﹤0.01% 1473
2024
Q1 		$257K Buy
17,359
+1,952
+13% +$22.7K 0.01% 1333
2023
Q4 		$125K Buy
+15,407
New +$80.6K ﹤0.01% 1455

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Personalized Indexing Management's IOVA Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Iovance Biotherapeutics (IOVA) stake by 33% in Q2 2026, buying an estimated $36.9K and bringing the position to 39,528 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Vanguard Personalized Indexing Management first reported a position in IOVA in Q4 2023 and has held it in 9 quarters since. The position peaked at $261K in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Vanguard Personalized Indexing Management held 39,528 shares of Iovance Biotherapeutics worth $164K as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 9,724 Iovance Biotherapeutics shares in Q2 2026, an estimated $36.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1965 holding.
  • Vanguard Personalized Indexing Management first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 9 quarters since.
  • Vanguard Personalized Indexing Management's Iovance Biotherapeutics position peaked at $261K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.